Site-of-care edits are payer utilization management policies that restrict where a patient can receive a provider-administered specialty drug. The edits typically deny coverage for drug administration in a hospital outpatient department (HOPD) when the payer determines that the drug could be safely administered in a physician office, ambulatory infusion center, or, in some cases, the patient's home. The policy is triggered at the prior authorization stage or at the claims level, and it is one of the most consequential access barriers for infused and subcutaneous specialty drugs that are billed under the medical benefit.
This article is for manufacturer market access teams, hub-services leads, provider network managers, and specialty pharmacy directors who need to understand how site-of-care edits work, how they interact with the broader trend toward site-neutral payment, and what the operational consequences are for drug uptake and patient access.
How site-of-care edits work
The clinical and financial logic
The payer rationale is straightforward: hospital outpatient facilities cost more than physician offices for the same drug administration. Under Medicare, a drug administered in an HOPD is reimbursed under the Hospital Outpatient Prospective Payment System (OPPS), which includes both a drug payment and a facility fee. The same drug administered in a physician office is reimbursed under the Medicare Physician Fee Schedule (MPFS) at ASP plus 4.3 percent (for drugs pass-through eligible) or at the established payment limit, with a lower facility component.
A 2026 analysis by the Berkeley Research Group (BRG), funded by PhRMA, found that 340B-eligible hospital outpatient departments, including off-campus locations, continue to represent a growing share of outpatient drug administrations under Medicare Part B. The BRG analysis reported that per-beneficiary Medicare spending on oncology drugs at 340B DSH hospitals increased substantially compared with non-340B sites, driven in part by the shift in site of care toward HOPDs. The cost differential between HOPD and physician office administration is the direct financial motivation for payer site-of-care edits.
From the payer perspective, redirecting infusion volume from HOPDs to physician offices or ambulatory infusion centers reduces total cost of care without changing the drug itself. Payers argue that the clinical setting does not affect drug efficacy for most stable chronic infusions.
How the edit is applied
Site-of-care edits operate at two levels:
Prior authorization for the site. The payer requires prior authorization not just for the drug but for the site of administration. If the provider requests HOPD administration, the payer applies clinical criteria to determine whether the hospital setting is medically necessary. If the criteria are not met, the authorization is denied for the HOPD site but may be approved for an alternative setting.
Claims-level editing. Some payers apply automated claim edits that deny HOPD facility claims for specific drug-administration combinations. The edit may trigger a request for medical records to justify the hospital setting, or it may auto-deny with an appeal pathway.
The scope of drugs affected
UnitedHealthcare's Commercial Medical Benefit Drug Policy for Provider Administered Drugs — Site of Care, effective January 1, 2026 (Policy Number 2026D0121S), lists hundreds of specialty medications subject to site-of-care review. The list includes:
- Immune checkpoint inhibitors: Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab), Libtayo (cemiplimab), Yervoy (ipilimumab), Imfinzi (durvalumab), and their biosimilar and combination products
- Inflammatory and autoimmune biologics: Remicade (infliximab), Orencia (abatacept), Stelara IV (ustekinumab), Actemra (tocilizumab), Simponi Aria (golimumab), Nucala (mepolizumab), Fasenra (benralizumab), and Ultomiris (ravulizumab)
- IV and subcutaneous immunoglobulin: multiple IVIG and SCIG products including Gammagard, Privigen, Octagam, Panzyga, Hizentra, Cuvitru, and HyQvia
- Enzyme replacement therapies: Fabrazyme (agalsidase beta), Elaprase (idursulfase), Vimizim (elosulfase alfa), Naglazyme (galsulfase), and Elelyso (taliglucerase)
- Rare disease biologics: Tegsedi (inotersen), Onpattro (patisiran), Oxlumo (lumasiran), Givlaari (givosiran), and Viltepso (viltolarsen)
Aetna's drug infusion/injection site-of-care policy similarly covers a broad range of provider-administered therapies. Aetna's policy states that "all follow-up doses need to follow our site-of-care policy" and that "in general, this means avoiding hospital outpatient care unless it's medically needed." Aetna also operates a separate Gene-Based, Cellular and Other Innovative Therapy (GCIT) network for cell and gene therapies, which requires all doses, including the first, to be administered at a GCIT-designated facility.
Highmark's Site of Care Drug Management Program, updated April 2026, explicitly states that the program "helps decrease the cost of care for these therapies by ensuring appropriate utilization of the drugs through medical policy and a prior authorization requirement." Highmark added immune checkpoint inhibitors to its site-of-care program effective September 2025, targeting PD-1 inhibitors (Keytruda, Opdivo, Jemperli, Libtayo), PD-L1 inhibitors (Tecentriq, Imfinzi, Bavencio), CTLA-4 inhibitors (Yervoy, Imjudo), and LAG-3 inhibitors (Opdualag).
The financial impact on providers and manufacturers
Hospital margin compression
When a site-of-care edit redirects an infusion from an HOPD to a physician office, the hospital loses both the drug margin and the facility fee. For 340B hospitals, the margin loss is significant. The American Cancer Society Cancer Action Network (ACS CAN), working with BRG, reported that oncology drugs represent approximately 41 percent of 340B purchases, and that a single oncologist can represent at least $1 million in annual 340B profits. Site-of-care edits that shift infusion volume out of 340B-eligible HOPDs directly reduce this margin.
Manufacturer implications
For manufacturers, site-of-care edits create several operational consequences:
Purchase pattern shifts. When infusions move from hospital outpatient to physician office settings, the purchasing channel changes. Buy-and-bill economics, ASP reimbursement dynamics, and specialty pharmacy distribution all differ between settings.
Access friction. A site-of-care denial can delay treatment while the provider appeals or reschedules at an alternative site. For chronic therapies like IVIG or periodic biologics, repeated site-of-care reviews at each authorization renewal create ongoing access friction.
Hub-services complexity. Manufacturer hub programs that assist with benefit verification and prior authorization must now also navigate site-of-care authorization requirements, which adds a layer of complexity to the support workflow.
Patient disruption. Patients who have been receiving infusions at a familiar hospital outpatient clinic may be required to switch to a new provider site. This is not just an inconvenience; it can affect adherence, particularly for patients with complex regimens or who require close monitoring.
CMS site-neutral payment expansion
The 2026 proposed rule
In the CY 2026 Hospital Outpatient Prospective Payment System proposed rule, CMS proposed applying site-neutral payment to drug administration services in excepted off-campus HOPDs. Under the proposal, payment rates for these services would be aligned with MPFS rates, reducing the payment differential that currently makes HOPD administration more lucrative.
Milliman estimated that the proposed site-neutral payment policy would reduce OPPS spending by $280 million in CY 2026, with $210 million in savings to Medicare and $70 million in reduced beneficiary cost-sharing. The policy would directly reduce hospital revenue for drug administration services performed at off-campus HOPDs.
The CMS CY 2026 OPPS Final Rule, issued November 21, 2025, estimated that total OPPS payments for CY 2026 would increase by approximately $1.77 billion compared with CY 2025 due to the market-basket update, but that providers subject to the 340B remedy offset would see payments reduced by $275 million.
Implications for commercial site-of-care edits
The CMS site-neutral payment expansion, if fully implemented, would reduce the financial incentive for commercial payers to enforce site-of-care edits, because the cost differential between HOPD and physician office would narrow. However, commercial payers have their own reimbursement structures, and the OPPS-to-MPFS alignment affects only Medicare. Commercial site-of-care edits are likely to persist as long as the HOPD cost differential exists in commercial contracts.
Medical necessity criteria for HOPD administration
Most payer policies allow HOPD administration when specific clinical criteria are met. Aetna's policy, for example, covers hospital outpatient therapy for up to 45 days when any of the following apply:
- Adverse reactions or medical risk: documented history of severe infusion reactions, anaphylaxis, or hemodynamic instability during prior infusions
- Access and safety challenges: patients requiring continuous monitoring due to comorbidities, complex vascular access, or need for emergency intervention capability
- Specific drug scenarios: certain drugs with known high rates of severe adverse events that require immediate access to resuscitation equipment and intensive monitoring
For immune checkpoint inhibitors specifically, Aetna's policy lists qualifying conditions including grade 2 to 4 bullous dermatitis, Stevens-Johnson syndrome, transaminitis, pneumonitis, acute pancreatitis, primary adrenal insufficiency, aseptic meningitis, encephalitis, transverse myelitis, myocarditis, pericarditis, and arrhythmias. The specificity of these criteria means that most stable patients receiving routine checkpoint inhibitor maintenance infusions will not qualify for HOPD administration.
UnitedHealthcare's policy similarly requires that hospital outpatient infusion services meet medical necessity criteria for specialty medications and IVIG/SCIG therapy, including claim submission for drugs listed in the policy's applicable HCPCS code table.
Mandatory site-of-service programs
Beyond prior authorization, some plans operate mandatory site-of-service programs that actively redirect patients to lower-cost settings. Molina Marketplace's Specialty Medication Administration Site of Care policy states that "patients receiving ongoing medical specialty drug infusions in an outpatient facility are required to transition the administration of their infusions to a home setting" when home infusion benefits are available and the patient and provider agree to the transition.
These mandatory programs go further than site-of-care edits. They do not simply deny HOPD coverage for future infusions; they require active transition of existing patients to alternative settings. For manufacturers, this means that patients who start therapy in a hospital setting may be forced to switch administration sites mid-treatment.
What market access teams should monitor
Policy expansion trajectory
Site-of-care edits are expanding in two dimensions: more payers are adopting them, and more drugs are being added to the lists. When UnitedHealthcare adds a drug to its Provider Administered Drugs — Site of Care policy, other commercial payers typically follow within 12 to 18 months. Manufacturers launching new infused or subcutaneous biologics should expect site-of-care review from day one.
HCPCS code assignment
Site-of-care edits are applied at the HCPCS code level. A new biologic that receives a temporary Q-code or is billed under a miscellaneous code (J3490, J3590, C9399) may initially escape site-of-care editing because the payer's claims system does not yet associate the code with the edit. Once a permanent J-code is assigned, the drug is immediately captured by existing edit programs. This creates a gap between launch and the activation of site-of-care restrictions, which manufacturers should anticipate in their launch access planning.
UnitedHealthcare's January 2026 update added several new drugs to its medication sourcing and site-of-care programs, including Imaavy (nipocalimab-aahu) with site-of-care requirements effective at launch, and Eydenzelt (aflibercept-boav), Itvisma (onasemnogene abeparvovec-brve), Opuviz (aflibercept-yszy), and Osvyrti (denosumab-desu) with medication sourcing requirements effective April 1, 2026.
Subcutaneous formulation launches
The trend toward subcutaneous formulations of previously IV-only biologics, such as Ocrevus Zunovo (ocrelizumab and hyaluronidase), Tecentriq Hybreza (atezolizumab and hyaluronidase), and Keytruda Qlex (pembrolizumab and berahyaluronidase), changes the site-of-care dynamics. Subcutaneous formulations are more amenable to administration in physician offices or even at home, which makes them more susceptible to site-of-care redirect. However, the first dose of many subcutaneous biologics still requires monitoring in a clinical setting, and payer policies may differ for first-dose versus maintenance-dose administration.
Operational recommendations for manufacturer teams
Track payer policy updates quarterly. UnitedHealthcare, Aetna, Cigna, and Elevance update their site-of-care drug lists and medical necessity criteria on predictable quarterly cycles. Assign someone on the market access or policy team to review each update and flag changes that affect your product.
Build site-of-care authorization into hub workflows. If your product is administered by infusion or injection under the medical benefit, your hub services program should screen for site-of-care requirements during benefit verification, not just during prior authorization. A drug may be approved but the site may be denied.
Model the impact on provider economics. When a site-of-care edit redirects patients from HOPDs to physician offices, the provider margin changes. For buy-and-bill products, this affects ASP dynamics, provider purchasing behavior, and demand forecasting. Include site-of-care redirect assumptions in your access models.
Engage with medical affairs on clinical criteria. The medical necessity criteria for HOPD administration are clinical. If your product has a safety profile that supports HOPD administration for certain patient subgroups, work with medical affairs to develop supporting documentation that providers can use in their prior authorization appeals.
Monitor CMS site-neutral rulemaking. The trajectory of CMS site-neutral payment policy will eventually reduce the commercial cost differential that drives site-of-care edits. Track OPPS proposed and final rules annually for provisions that narrow the HOPD-to-MPFS payment gap.
Sources
- UnitedHealthcare Commercial Medical Benefit Drug Policy: Provider Administered Drugs — Site of Care, Policy Number 2026D0121S, Effective January 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/provider-administered-drugs-soc.pdf
- Aetna Drug Infusion/Injection Site-of-Care Policy. https://www.aetna.com/health-care-professionals/utilization-management/drug-infusion-site-of-care-policy.html
- Highmark Site of Care Drug Management Program, Updated April 2026. https://providers.highmark.com/policies-and-programs/pharmacy-programs/site-of-care-drug-management.html
- BRG (Berkeley Research Group), "Site-of-Care Shift for Physician-Administered Drug Therapies: 2026 Update," January 2026. https://media.thinkbrg.com/wp-content/uploads/2026/02/09112623/Site-of-Care-Refresh-2026_02092026.pdf
- ACS CAN / BRG, "The Intersection of 340B and Cancer Care," March 2025. https://www.fightcancer.org/sites/default/files/national_documents/340b_and_cancer_care_-_final_3-12-25.pdf
- CMS CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Final Rule. https://www.cms.gov/newsroom/fact-sheets/calendar-year-2026-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center
- Milliman, "Site-neutral payment: 5 considerations for hospitals and health systems." https://www.milliman.com/en/insight/site-neutral-payment-5-considerations-hospitals
- Molina Marketplace Specialty Medication Administration Site of Care Policy. https://www.molinamarketplace.com/marketplace/-/media/Molina/PublicWebsite/PDF/Common/Specialty-Medication-Administration-Site-of-Care-Coverage-Criteria-Policy_v2
- 21 CFR 314.70, Supplements and Other Changes to an Approved Application. https://www.ecfr.gov
